CL2023001680A1 - Proteínas inmunoglobulinas que se unen a agonistas npr1. - Google Patents

Proteínas inmunoglobulinas que se unen a agonistas npr1.

Info

Publication number
CL2023001680A1
CL2023001680A1 CL2023001680A CL2023001680A CL2023001680A1 CL 2023001680 A1 CL2023001680 A1 CL 2023001680A1 CL 2023001680 A CL2023001680 A CL 2023001680A CL 2023001680 A CL2023001680 A CL 2023001680A CL 2023001680 A1 CL2023001680 A1 CL 2023001680A1
Authority
CL
Chile
Prior art keywords
npr1
agonists
bind
immunoglobulin proteins
immunoglobulin
Prior art date
Application number
CL2023001680A
Other languages
English (en)
Spanish (es)
Inventor
Neil Stahl
Michael Dunn
Lori Morton
Tammy Huang
Ishita Chatterjee
Vishal Kamat
Ashique Rafique
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2023001680A1 publication Critical patent/CL2023001680A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2023001680A 2020-12-18 2023-06-09 Proteínas inmunoglobulinas que se unen a agonistas npr1. CL2023001680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063127959P 2020-12-18 2020-12-18

Publications (1)

Publication Number Publication Date
CL2023001680A1 true CL2023001680A1 (es) 2024-03-08

Family

ID=79687048

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001680A CL2023001680A1 (es) 2020-12-18 2023-06-09 Proteínas inmunoglobulinas que se unen a agonistas npr1.

Country Status (12)

Country Link
US (2) US12325752B2 (enExample)
EP (1) EP4263616A1 (enExample)
JP (1) JP2024503784A (enExample)
KR (1) KR20230132468A (enExample)
CN (1) CN116964101A (enExample)
AU (1) AU2021401415A1 (enExample)
CA (1) CA3202629A1 (enExample)
CL (1) CL2023001680A1 (enExample)
CO (1) CO2023009498A2 (enExample)
IL (1) IL303542A (enExample)
MX (1) MX2023007023A (enExample)
WO (1) WO2022133239A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202101037QA (en) 2018-10-23 2021-02-25 Regeneron Pharma Anti-npr1 antibodies and uses thereof
CA3202629A1 (en) 2020-12-18 2022-06-23 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to npr1 agonists
WO2023064769A1 (en) * 2021-10-11 2023-04-20 Regeneron Pharmaceuticals, Inc. Methods of effecting a hemodynamic change by administering an anti-npr1 antibody
US20230250170A1 (en) * 2021-12-06 2023-08-10 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004011618A2 (en) 2002-07-29 2004-02-05 Hmgene, Inc. Methods of identifying adipocyte specific genes, the genes identified, and their uses
US20080214437A1 (en) 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP2162464A1 (en) 2007-06-06 2010-03-17 Boehringer Ingelheim International GmbH Natriuretic fusion proteins
CA2745288A1 (en) 2008-12-03 2010-06-10 Alisa Kabcenell Antibodies for guanylyl cyclase receptors
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US9451770B2 (en) 2012-06-08 2016-09-27 Charles Despres Method of activating immune response in plants
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016131943A1 (en) 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes
WO2017209553A2 (ko) 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 환자 유래 세포를 이용한 항체 스크리닝 방법
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US20190135804A1 (en) 2017-11-03 2019-05-09 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Compositions and methods for the inhibition of pruritus
SG11202101037QA (en) 2018-10-23 2021-02-25 Regeneron Pharma Anti-npr1 antibodies and uses thereof
US20220025070A1 (en) * 2018-12-18 2022-01-27 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
KR20220019785A (ko) * 2019-06-12 2022-02-17 노파르티스 아게 나트륨이뇨 펩티드 수용체 1 항체 및 사용 방법
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
CA3202629A1 (en) 2020-12-18 2022-06-23 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to npr1 agonists
US20230250170A1 (en) 2021-12-06 2023-08-10 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof

Also Published As

Publication number Publication date
JP2024503784A (ja) 2024-01-29
CA3202629A1 (en) 2022-06-23
EP4263616A1 (en) 2023-10-25
AU2021401415A9 (en) 2024-10-17
CO2023009498A2 (es) 2023-08-28
US20250333524A1 (en) 2025-10-30
WO2022133239A1 (en) 2022-06-23
AU2021401415A1 (en) 2023-07-13
US20220195058A1 (en) 2022-06-23
CN116964101A (zh) 2023-10-27
MX2023007023A (es) 2023-08-29
IL303542A (en) 2023-08-01
KR20230132468A (ko) 2023-09-15
US12325752B2 (en) 2025-06-10

Similar Documents

Publication Publication Date Title
CL2023001680A1 (es) Proteínas inmunoglobulinas que se unen a agonistas npr1.
HUE062777T2 (hu) SARS-CoV-2 elleni antitestek
CO2021011140A2 (es) Anticuerpos que reconocen tau
CU20160118A7 (es) Moléculas de anticuerpo que se unen a tim-3
CL2018000699A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
CR20230573A (es) ANTICUERPOS ANTI-SIRP-alfa
CO2021011644A2 (es) Anticuerpos que reconocen tau
CL2021001158A1 (es) Anticuerpos que reconocen tau
DK4214240T3 (da) Anti-ccr8-antistoffer
EP3887745C0 (en) SILENCER FOR FIREARM
EP4277927A4 (en) NEW ANTI-GREMLIN-1 ANTIBODIES
IL304800A (en) Bispecific antibody
CU20210039A7 (es) Anticuerpos que reconocen tau
EP4144370A4 (en) BISPECIFIC ANTIBODY
EP4348448A4 (en) AUTOMATIC CLASSIFICATION PIPELINE
IL313454A (en) Off-target prediction method for antigen-recognition molecules binding to mhc-peptide targets
EP4532558A4 (en) ANTI-ROR1 ANTIBODIES
EP4392455A4 (en) ANTI-CD-25 ANTIBODIES
EP3759663A4 (en) AUTOMATED DISPATCH OPTIMIZATION
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células
DK4258865T3 (da) Tungkæde-antistoffer
IL311043A (en) Anti-il-11rα antibodies
IL299767A (en) Anti-αlpha-4-βeta-7 antibodies
EP4222597A4 (en) COORDINATION OF TASK RESPONSIBILITIES
DK3671200T3 (da) Ce-western-applikationer til udvikling af antistof